Advances in dual-targeting inhibitors of HDAC6 for cancer treatment

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Histone Deacetylase 6 (HDAC6) regulates key cellular functions including motility, endocytosis, autophagy, apoptosis, and protein trafficking.
• HDAC6 dysregulation is implicated in various diseases, notably cancer, neurodegenerative disorders, and immune disorders, driving therapeutic interest.
• Single-target inhibitors risk drug resistance, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To review and discuss published design strategies for dual-targeting inhibitors of HDAC6.
• To highlight the potential of HDAC6 hybrid molecules in overcoming limitations of traditional combination therapies.
• To provide insights for developing novel HDAC6 dual-targeting inhibitors for oncology and related fields.

Main Methods:

• Literature review of published HDAC6 dual-targeting inhibitor design strategies.
• Analysis of the advantages of hybrid molecules over traditional combination therapies.
• Discussion of therapeutic implications for cancer and other diseases.

Main Results:

• Dual-targeting strategies, particularly HDAC6 hybrid molecules, offer enhanced therapeutic efficacy.
• Hybrid molecules can mitigate side effects and reduce the risk of drug resistance compared to combination therapies.
• The review summarizes current design approaches for these novel inhibitors.

Conclusions:

• HDAC6 hybrid molecules represent a promising approach for developing innovative therapies.
• Dual targeting of HDAC6 holds significant potential for improving treatment outcomes in oncology and other diseases.
• Further research into novel HDAC6 dual-targeting inhibitors is essential to meet unmet clinical needs.